<DOC>
	<DOC>NCT00159640</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of chronic pain following a shingles infection.</brief_summary>
	<brief_title>Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<criteria>Patients must have pain present for more than 3 months after the healing of shingles skin rash. Patients at screening must have a score &gt;=40 mm on the pain visual analogue scale. Patients with poor renal function. Patients with other severe pain, that may impair the selfassessment of the pain due to shingles. Patients with abnormal electrocardiogram.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>